American Diabetes Association And Entelos Broaden Access To Testing With " Virtual Mice "

The American Diabetes Association ( ADA ) and Entelos, Inc. ( LSE: ENTL ) announced extending its in silico ( computer simulation ) diabetes research center capability and offering free access to Entelos' Realab™ " virtual mice " testing platform to all ADA health professional members. Realab allows direct web access to Entelos' state-of-the-art computer model of type 1 diabetes, enabling scientists and clinicians an unparalleled ability to investigate onset, progression, and treatment of diabetes.

Using Realab, researchers can conduct simulations on drugs, drug combinations, dose levels, dosing regimens, therapeutic targets, biological pathways and functions on the primary animal model used to study type 1 diabetes. Realab's virtual environments allow investigators to preview the likely effects of different therapeutic interventions, helping to inform the optimal design of lab experiments and clinical protocols.

The ADA and Entelos collaborated to develop Type 1 Diabetes PhysioLab� platform, a large scale computer-based mathematical model of non-obese diabetic ( NOD ) mouse, which is simulation engine behind Realab for type 1 diabetes.

" There are now two ways that our members can benefit from Entelos' cutting-edge simulation technology, " said Richard Kahn, Ph. D. , chief scientific and medical officer, American Diabetes Association. " The first is through diabetes research center capability, which is available via a grant process. The second is through direct online access of Entelos' Realab for type 1 diabetes research, which we are now pleased to offer for free to all ADA health professional members. We believe that this won't only accelerate adoption of this innovative approach, it'll also make a big impact on finding new therapies for type 1 diabetes, which primarily affects children and young adults. '

" One of the greatest disappointments for pharmaceutical industry is having experimental compounds that show early promise in animals that later fail miserably when tested in humans, " stated James Karis, president and CEO of Entelos. " In building our initial model of a 'virtual mouse', scientific teams at Entelos discovered subtle but important differences between species that can have a big impact on interpreting results of animal studies and on designing clinical trials. Our models and predictive platforms help to better translate results and design experiments to make animal studies more meaningful and relevant for finding effective medicines for patients. We plan to increase access to Entelos' powerful simulation technology to enhance researchers' capabilities to rapidly test 'virtual mice' and 'virtual patients' and ultimately use fewer animals, run more decisive clinical trials, and save time and money. "

Realab currently has a virtual environment available for type 1 diabetes. Environments for rheumatoid arthritis, cardiovascular disease and type 2 diabetes are under development by Entelos. Details regarding Realab can be found at http: //www. entelos. com

About Realab™

Realab™ was developed by Entelos to provide scientists and clinicians with personalized web-based access to Entelos' award-winning PhysioLab� technology and computer models of human and animal disease physiology. Realab's virtual environments allow investigators to preview likely effects of different therapeutic interventions in advance, helping to inform the optimal design of research and clinical protocols in real world.

The Realab web-based tool facilitates design and submission of experiments and clinical protocols. The investigator uses a menu system to select from available predefined options for each simulation analysis including drugs, drug combinations, dose levels, dosing regimens, therapeutic targets, biological pathways, functions, patient or animal phenotypes and sampling intervals.

Once a Realab protocol is submitted, simulation results are available in Realab within 24 hours for later analysis at user's convenience. Researchers can visualize the predicted outcome of the Realab protocol using graphs and other tools to investigate underlying biological mechanisms responsible for each predicted outcome.

Realab currently has a virtual environment available for type 1 diabetes with predefined experiments, about a dozen therapies and 75 possible model outputs. Access to Realab simulations for non-ADA members can be purchased online or via purchase order.

About Type 1 Diabetes PhysioLab Platform

The Entelos� Type 1 Diabetes PhysioLab� platform is a large-scale, mathematical model of non-obese diabetic ( NOD ) mouse designed to support research in type 1 diabetes. The platform captures the physiology of pancreatic cell autoimmunity and tolerance from birth until disease onset. Virtual NOD mice are constructed using equations that mathematically represent cellular functions and biochemical interactions in tissues critical for the pathogenesis of type 1 diabetes. The model encompasses two main tissues: pancreatic lymph nodes ( PLN ) and pancreatic islets. Antigen and antigen-presenting cells traffic from islets to the PLN, and conversely, lymphocytes activated in PLN can enter blood and be recruited to islets. Functions at biochemical and cellular levels are integrated and dynamic relationships over time quantitatively linked via mathematical equations, making simulation and prediction of biological outcomes possible.

About Entelos

Entelos, Inc. ( http: //www. entelos. com ) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, " virtual patients', and toxicology reference systems to develop safer and more effective drugs and support pharmaceutical R&D and commercialization. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos provides customized technology and research services to global pharmaceutical and health-care companies in cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis ( anemia ) , cholesterol metabolism, and skin sensitization. The Company is also developing a model in oncology and is collaborating with FDA to build a model of drug-induced liver injury. Entelos also offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys Ltd.

About the American Diabetes Association

The American Diabetes Association is nation's premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association has offices in every region of country, providing services to hundreds of communities. The Association's commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into cure, prevention, and treatment of diabetes and its complications.

American Diabetes Association

Feel good is great. Learn this way and use it.

Trusted information about Zyrtec.

uses of Zyrtec Zyrtec is an antihistamine which provides relief of seasonal and perennial allergy symptoms such as watery eyes, runny nose ( rhinitis ) , itching eyes, and sneezing. It's also used for hives.

how to use of Zyrtec Take Zyrtec by mouth once a day; or use as directed by your doctor. Zyrtec may be taken with or without food.

Do not increase your dose or take this more often than directed.

Don't take Zyrtec for several days before allergy testing since test results can be affected.

Inform your doctor if your condition persists or worsens.

side effects of Zyrtec Drowsiness, fatigue and dry mouth may occur while use Zyrtec. In children, stomach pain and vomiting may occur while use Zyrtec. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed Zyrtec because he or she has judged that benefit to we is greater than risk of side effects. Many people using Zyrtec don't have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur:

A serious allergic reaction to Zyrtec is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include:

This isn't a complete list of possible side effects. If we notice other effects not listed above, contact your doctor or pharmacist.

precautions of Zyrtec Before taking Zyrtec, tell your doctor or pharmacist if we are allergic to it; or to hydroxyzine; or if we have any other allergies.

Before using Zyrtec, tell your doctor or pharmacist your medical history, especially of:

Zyrtec may make we drowsy; use caution engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages.

Caution is advised when using Zyrtec in the elderly because they may be more sensitive to the effects of drug, especially drowsiness effect.

Zyrtec should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor.

Zyrtec passes into breast milk. Breast-feeding isn't recommended while using Zyrtec.

interactions of Zyrtec Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring we for them. Don't start, stop, or change dosage of any medicine before checking with them first.

Before using Zyrtec, tell your doctor or pharmacist of all prescription and nonprescription products we may use, especially of drugs that cause drowsiness such as:

Check labels on all your medicines ( e. g. , cough-and-cold products ) because they may contain drowsiness-causing ingredients. Ask your pharmacist about safe use of those products.

This document doesn't contain all possible interactions. Therefore, before using Zyrtec, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share list with your doctor and pharmacist.

Zyrtec with EU shipping

Wrinkle Relief: Injectable Cosmetic Fillers. Injectable wrinkle fillers can restore a smoother appearance to your face, but here's what to consider before having this cosmetic procedure done.

Nexium Approved for Children 1 to 11 Years Old. Nexium, a drug that treats gastroesophageal reflux disease (GERD), has received FDA approval for shortterm, lowdosage use in children ages 1 to 11 years old

Prepare for Hurricanes and Floods: Advice From FDA. This updated article gives tips on how to keep food, medical products, and pets safe during an emergency.

Getting Up to Date on Glucose Meters. FDA is reminding consumers to only use the test strips that are recommended for use with their glucose meter.

Contaminated Nipple Cream. FDA is warning nursing mothers not to buy or use Mommy's Bliss Nipple Cream because it contains potentially harmful ingredients.

Sentinel System to Monitor Medical Product Safety. FDA's new Sentinel Initiative aims to establish a national electronic system for tracking medical product performance.

FDA 101: Advisory Committees. FDA's Advisory Committees are critical to the agency's product review process. Find out the basics of putting special government employees with different perspectives on such scientific committees.

Prepare for Hurricanes and Floods: Advice From FDA. This updated article gives tips on how to keep food, medical products, and pets safe during an emergency.

Facebook Said To Pose 'Mental Risks' To Teens. Teens who are hooking up with the rising social networking sites face potential dangers, according to a psychiatrist. Fri, 4 Jul 2008 01:06:20 GMT.

Study: Compound Found In Red Wine Prevents Age-Related Maladies. A compound found in grapes and red wine has been seen to help with age-related health concerns, a new Harvard study has found. Fri, 4 Jul 2008 04:47:51 GMT.

Washington's Doctor-Assisted Suicide Initiative Gathers Public Support. Supporters of a doctor-initiated death initiative turned in an estimated 320,000 signatures Tuesday to the Secretary of State's Office. The signatures are more than enough to send Initiative 1000 to voters in November. Fri, 4 Jul 2008 05:22:42 GMT.

Texas Doctors Who Still Accept New Medicare Patients Down By 32 Percent. Doctors in Texas are shying away from taking in new Medicare patients because of reductions in reimbursements. Fri, 4 Jul 2008 11:48:10 GMT.